Treglia Giorgio, Raditchkova Mariana, Giovanella Luca, Stelmes Jean-Jacques, Bosetti Davide G, Martucci Francesco
Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Diagnostics (Basel). 2021 Sep 13;11(9):1669. doi: 10.3390/diagnostics11091669.
We describe the case of a 74-year-old female patient previously treated with radiation therapy for a meningioma of the skull base and with surgery for a right tympanic paraganglioma. After the morphological progression of the meningioma demonstrated by magnetic resonance imaging (MRI), the patient underwent somatostatin receptor positron emission tomography/computed tomography (SR-PET/CT) with Gallium-68 DOTATATE for restaging. This examination showed increased somatostatin receptor expression by the meningioma and confirmed its extension as already assessed by MRI (endocranial extension, skull base involvement and invasion of the right orbit). Furthermore, SR-PET/CT detected two small right jugulotympanic pararagangliomas with high somatostatin receptor expression. Lastly, SR-PET/CT demonstrated that this patient would be an ideal candidate for peptide receptor radionuclide therapy (PRRT) that can be used for the treatment of progressive/treatment-refractory meningiomas and relapsed paragangliomas with high somatostatin receptors expression, both conditions coexisting in this case.
我们描述了一名74岁女性患者的病例，该患者曾因颅底脑膜瘤接受放射治疗，并因右侧鼓室副神经节瘤接受手术治疗。在磁共振成像（MRI）显示脑膜瘤出现形态学进展后，患者接受了使用镓-68 DOTATATE的生长抑素受体正电子发射断层扫描/计算机断层扫描（SR-PET/CT）进行再分期。该检查显示脑膜瘤的生长抑素受体表达增加，并证实了其如MRI已评估的那样的扩展情况（颅内扩展、颅底受累及右侧眼眶侵犯）。此外，SR-PET/CT检测到两个右侧颈鼓室副神经节瘤，其生长抑素受体表达较高。最后，SR-PET/CT表明该患者将是肽受体放射性核素治疗（PRRT）的理想候选者，PRRT可用于治疗生长抑素受体高表达的进行性/治疗难治性脑膜瘤和复发性副神经节瘤，这两种情况在该病例中同时存在。
